Search Results
Dec 15, 2025, 08:30 ET Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors
LNK001 for the treatment of renal cell carcinoma ("RCC"), is on track for an Investigational New Drug (IND) application and initiation of dosing in a Phase I clinical trial in 2026. LNK001 targets two antigens that are uniquely and highly co-expressed in most RCC tumors. LNK001 is designed to enable tumor-specific
More news about: Link Cell Therapies
Dec 04, 2025, 07:30 ET Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
(non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally
More news about: Trevi Therapeutics, Inc.
Nov 25, 2025, 08:42 ET REACH Trial and The Concinnity Company™ Collaborate to Enhance Investigator-Initiated Trial Oversight with Cloud Concinnity®
Nov. 25, 2025 /PRNewswire/ -- The Concinnity Company™ today announced that the REACH Trial and Coordinating Center (RCC) is using Cloud Concinnity® to strengthen oversight for Data Monitoring Committees (DMCs), steering committees, operations committees, and other academic
More news about: The Concinnity Company
Nov 20, 2025, 00:30 ET Lumina Datamatics Partners with Dhana Sundarambal Charitable Society for Pond Restoration Project in Puducherry
reservoir, strengthen the local ecosystem, and improve water conservation in the region. The project includes activities such as masonry and structural work, RCC column construction, grading, and revetment to reinforce the pond's embankments. The restoration will be implemented in multiple stages with completion
More news about: Lumina Datamatics Limited
Nov 14, 2025, 11:10 ET OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion
months. The collaboration aims to build a next-generation immuno-oncology platform leveraging synergistic mechanisms of action for renal cell carcinoma (RCC) and other advanced solid tumors. "I am delighted to step into the role of CEO as we enter an exciting new phase where Vaximm's
More news about: OSR Holdings
Nov 13, 2025, 16:05 ET Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
(non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally
More news about: Trevi Therapeutics, Inc.
Nov 06, 2025, 16:05 ET Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally
More news about: Trevi Therapeutics, Inc.
Nov 06, 2025, 08:00 ET OncoHost Wins 'Proteomics Innovation of the Year' at the BioTech Breakthrough Awards
survival (PFS) and overall survival (OS). The PROphet® proteomic signature has also demonstrated predictive value across melanoma, renal cell carcinoma (RCC), HPV-associated malignancies, triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and colorectal cancer. In
More news about: OncoHost
Nov 04, 2025, 09:00 ET AVEO Oncology, an LG Chem company, and HiberCell Enter Into an Exclusive Development and Option Agreement for First-in-Human Compound
our commitment to RCC patients," said Michael P. Bailey, President and CEO of AVEO. "HC-5404 has shown promising activity combined with VEGFR TKIs which makes pairing it with tivozanib in RCC a logical first phase of development. The combinability with our current portfolio in RCC, coupled with the opportunity
More news about: AVEO, an LG Chem company
Nov 04, 2025, 07:30 ET Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally
More news about: Trevi Therapeutics, Inc.
Nov 03, 2025, 08:08 ET Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025
dose adjustment is recommended for patients with DTC, RCC, or EC and mild or moderate hepatic impairment. LENVIMA concentrations may increase in patients with DTC, RCC, or EC and severe hepatic impairment. Reduce the dose for patients with DTC, RCC, or EC and severe hepatic impairment.
More news about: Eisai Inc.
Oct 18, 2025, 03:00 ET Florida Cancer Specialists & Research Institute Shaping the Future of Cancer Care at Global Congress
analysis of 3 phase I clinical trials.Farnesyltransferase inhibitor (FTI) KO-2806 in combination with cabozantinib (cabo) in renal cell carcinoma (RCC): Preliminary results from FIT-001 Phase 1 trial.Single-agent divarasib experience in patients with KRAS G12C-positive pancreatic adenocarcinoma
More news about: Florida Cancer Specialists & Research Institute
Oct 14, 2025, 02:19 ET Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation, at the 2025 ESMO Annual Meeting
including TAM (TYRO3, AXL, and c-MER), are critical in creating environment conducive to tumor development in several cancers such as HNSCC, CRC, HCC, and RCC. GNTbm-TKI is a novel multi-targeted TKI, showing induction of immune activation in the tumor microenvironment (TME), that indicates the potential application
More news about: Great Novel Therapeutics Biotech & Medicals Corporation
Oct 08, 2025, 07:30 ET Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally
More news about: Trevi Therapeutics, Inc.
Oct 02, 2025, 08:08 ET Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775
dose adjustment is recommended for patients with DTC, RCC, or EC and mild or moderate hepatic impairment. LENVIMA concentrations may increase in patients with DTC, RCC, or EC and severe hepatic impairment. Reduce the dose for patients with DTC, RCC, or EC and severe hepatic impairment.
More news about: Eisai Inc.
Sep 18, 2025, 07:30 ET Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that data from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC, will be highlighted in two poster presentations at the
More news about: Trevi Therapeutics, Inc.